Cogent Biosciences Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$377.2MTTM through 30 Jun 2026
Free Cash Flow -$309.2MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-70.8%ROE
-45.2%ROA
Balance Sheet Health
Debt / Equity0.08x
Current Ratio13.57x
Net Debt-$136.9Mnet cash position
Cash & Equivalents$181.2M
Quality Metrics
Altman Z-Score8.46
Piotroski F-Score1 / 9
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2020: $7.9M
Diluted EPS-$2.16TTMFY2025: $-2.55
Dividend
No dividend
Capital Allocation
R&D Spend$290.7M
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.